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CystoscopyAbstract Background: The authors evaluated the role of photodynamic cystoscopy in the detec-
tion of additional urothelial lesions, mainly carcinoma in situ, that would not be detected solely
with white light cystoscopy, leading to disease understaging.
Methods: From 2009 to 2011, 70 patients underwent white light cystoscopy, followed by photody-
namic cystoscopy (blue light system, Karl Storz, Tuttlingen, Germany). Preoperatively they were
instilled intravesically with 50 ml of Hexvix (Hexaminolevulinate hexylester). We recorded all
lesions found with white light cystoscopy and the additional lesions revealed by blue light cys-
toscopy. Afterward all lesions were removed and sent for pathologic evaluation.
Results: Seventeen patients (24.3%) had primary tumors while 53 patients (75.7%) had recurrent
disease. In 53 out of 70 patients (75.7%) white light cystoscopy revealed urothelial lesions. In the
rest 17 patients who had no findings with white light cystoscopy, blue light cystoscopy revealed 7
cases of Cis (41.2%) and 8 cases of dysplasia (47%). In the group of patients with visible lesions
in white light cystoscopy photodynamic cystoscopy revealed additional carcinoma in situ in 22
patients. Altogether additional carcinoma in situ cases found with the aid of photodynamic cys-
toscopy were 29 out of 70 cases (41.4%).
Conclusions: Photodynamic cystoscopy is the most efficient diagnostic procedure for flat urothelial
lesions and especially for carcinoma in situ. It is significantly more sensitive than conventional white
light cystoscopy in Cis diagnosis, thus reducing understaging of the disease and consequently
improving recurrence and progression rates.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Bladder cancer is a very frequent neoplasm (the fourth most
frequent cancer in men and the ninth in women) [1,2]. In
2006 in Europe 104.400 new patients with bladder cancer were
diagnosed accounting for 6.6% of all cancers in men and 2.1%
in women. Male to female ratio is 3.8–1. Bladder cancer is
responsible for 4.1% of deaths due to cancer in men and
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rise in bladder cancer diagnosis was noticed, which, however,
was suppressed the last years and in some countries totally
disappeared due to well organized smoking cessation programs
[4].
The cornerstone of bladder neoplasm diagnosis is cysto-
scopy, also playing the most important role in the follow-up
of patients with bladder cancer history. However very small
Ta or T1 tumors can be missed with the rates of unnoticed
tumors varying from 3.4% to 20.6% for single tumors and
from 7.4% to 45.8% in cases of multiple tumors [5].
The major diagnostic disadvantage of cystoscopy is its low
sensitivity for the diagnosis of flat urothelial lesions, especially
for carcinoma in situ (Cis). Flat urothelial lesions are not
always visible or are very often difficult to distinguish from
normal epithelium. According to 2004 WHO classification, flat
urothelial lesions are dysplasia, urothelial hyperplasia, reactive
atypia, atypia of unknown significance and carcinoma in situ
[6]. Among these lesions carcinoma in situ is the most impor-
tant and most dangerous neoplasm as it is a flat, high grade,
non muscle invasive cancer. It is found as a primary lesion
in 1%-3% of all urothelial malignancies or it can be found
as a secondary cancer during the follow-up of patients with
previous exophytic tumors, or simultaneously with other
tumors. In the last case it accompanies 5% - 19% of non
muscle invasive tumors and 45% - 65% of muscle invasive
neoplasms [7]. Patients with Cis have 40% to 83% possibility
to develop muscle invasive cancer if left untreated, especially
if they have concurrent papillary tumors [8]. The presence
of Cis is an independent prognostic factor for recurrence,
progression and disease specific mortality [9]. Cystoscopy can
diagnose Cis in 38.1–71.4% of cases. This means that a large
number of Cis lesions are missed thus worsening prognosis
of these patients [10].
Photodynamic cystoscopy came to the fore in order to
overcome these drawbacks of classical cystoscopy. This tech-
nique is based on the selective concentration of photosensitiz-
ing agents in neoplastic cells of bladder urothelium, which then
emit fluorescence that can be visualized with blue light, using
the proper equipment [11,12].Materials and methods
This study was approved by the Institutional Review Board of
Laiko Athens Hospital. Records of patients with primary or
recurrent bladder cancer from 2009 to 2011 to the department
of urology, Laiko hospital were retrospectively reviewed.
From 2009 to 2011, 70 patients (66 men and 4 women) aged
25 to 82 years old (mean age 66.4 ± 9 years) were enrolled in
this study.
Provided they had negative urine culture, 50 ml Hexvix
(Hexaminolevulinate Hexylester) was instilled via a 10F
Nelaton catheter in patients’ bladder 1 h preoperatively.
After keeping the solution for 1 h in their bladder, the patients
were asked to urinate before they were carried to the surgery
room. The time frame between drainage of the drug and
inspection of the bladder was 60 min. This particular time
frame was important not to be exceeded, to avoid possible
distortion of visualization with blue light.
The equipment used was Karl Storz Photodynamic
Diagnostic D-Light C (PDD) System. The system includes aD-Light-C light Source and a Fluid Light Cable, a PDD cys-
toscope, an Endovision Tricam SL Camera Control Unit
and a PDD Camera Head.
In the operating room first cystoscopy was performed with
white light and all visible lesions were recorded. Cystoscopy
with the blue light system followed and all additional lesions
were recorded. Consequently all lesions (visible with white
and blue light) were removed and sent separately for patho-
logic evaluation. A biopsy sample from normally appearing
urothelium was taken.
The biopsy specimens were all evaluated by the same
pathologist according to 2004 WHO classification of urothelial
tumors and 2002 TNM staging system.
Results
The medical records of 70 patients with primary or recurrent
bladder cancer who had received surgical treatment from
2009 to 2011 were retrospectively reviewed. Among them were
66 males (91.7%) and 4 females (8.3%), whose age ranged
from 25 to 82 years, with an average of 66.4 ± 9 years.
Primary tumors were detected in 17 patients (24.3%) while 53
patients (75.7%) had recurrent disease. In those cases of recurrent
disease primary lesions were Ta low grade in 29 patients (54.7%),
Ta high grade in 5 patients (9.4%), T1 low grade in 4 patients
(7.5%), T1 high grade in 14 patients (26.4%) and Ta with
synchronous Cis in 1 patient (1.9%). The demographic and
clinicopathological data are shown in Table 1.
In 53 out of 70 patients (75.7%) white light cystoscopy
revealed urothelial lesions. Namely these lesions were Ta low
grade (12 cases, 22.6%), Ta high grade (6 cases, 11.3%), T1
low grade (2 cases, 3.8%), T1 high grade (12 cases, 22.6%),
Cis (8 cases, 15.1%), Ta with concurrent Cis (1 case, 1.9%),
T1 with concurrent Cis (4 cases, 7.5%), T2 (1 case, 1.9%),
dysplasia (6 cases, 11.3%) and denuding cystitis (1 case, 1.9%).
The results of positive white light cystoscopy cases are summa-
rized in Table 2.
All subjects who were positive to white light cystoscopy had
additional lesions with fluorescence cystoscopy. Additional
Carcinoma in situ was detected in 22 patients with photo-
dynamic cystoscopy (Table 3), dysplasia, reactive atypia and
denuding cystitis in 21, 3 and 7 patients respectively.
In the rest of the 17 patients with no findings with white
light cystoscopy, blue light cystoscopy revealed lesions that
would be otherwise missed. More specifically these lesions were
Cis (7 cases, 41.2%), dysplasia (8 cases, 47%), denuding cystitis
(1 case, 5.9%) and reactive atypia (1 case, 5.9%) (Table 4).
Discussion
As mentioned above cystoscopy may be the cornerstone of
bladder cancer diagnosis and follow-up. Nevertheless it can
sometimes fail in the diagnosis of urothelial tumors in 3.4%
to 45.8% of cases of Ta or T1 tumors [5]. Its diagnostic efficacy
is even smaller for flat urothelial lesions and more specifically
for carcinoma in situ. Cis diagnosis is based on the combina-
tion of urine cytology with cystoscopy and biopsy of the bladder.
The diagnosis rate of Cis with conventional cystoscopy (white
light) varies in published studies from 38.1% to 71.4% [10],
which indicates that conventional cystoscopy may miss a sig-
nificant number of Cis lesions. This is of major importance,
Table 1 Demographic data.
Patients 70
Men 66 (91.7%)
Women 4 (8.3%)
Primary disease 17 (24.3%)
Recurrent disease 53 (75.7%)
Table 2 Lesions visible with white light cystoscopy.
Lesion No
Ta low grade 12 (22.6%)
Ta high grade 6 (11.3%)
T1 low grade 2 (3.8%)
T1 high grade 12 (22.6%)
Cis 8 (15.1%)
Ta + Cis 1 (1.9%)
T1 + Cis 4 (7.5%)
T2 1 (1.9%)
Dysplasia 6 (11.3%)
Denuding cystitis 1 (1.9%)
Table 3 Additional Cis found with the aid of photodynamic
cystoscopy (in patients with positive white light cystoscopy).
White light
histology
Additional Cis with photodynamic
cystoscopy
Ta low grade 9
Ta high grade 6
T1 low grade 1
T1 high grade 2
Dysplasia 3
Denuding cystitis 1
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potential which, if left untreated, has 40% to 83% possibility
to progress into muscle invasive disease, especially if it is
concurrent to other papillary tumors of the bladder and thus
the risk of metastatic disease increases [9]. Therefore it is of
great significance to increase the sensitivity of our diagnosticTable 4 Lesions visible only with photodynamiprocedures in order to avoid understaging of the disease and
prognosis deterioration.
In the present study, the additional carcinoma in situ cases
found with the aid of photodynamic cystoscopy were 29 out of
70 cases (41.4%). This sum arises from the 22 additional Cis
found in patients with other lesions in white light cystoscopy
plus the 7 cases of Cis that were revealed with blue light imag-
ing in the group of 17 patients with no findings at all in white
light cystoscopy. Taking in account that Cis is a high grade
malignancy that can deteriorate the natural history of the
disease we can declare that in 41.4% of the patients the disease
was understaged according to white light cystoscopy findings.
Consequently all these cases would have missed and thus
41.4% of our patients would be understaged with obvious
unfavorable effects in the course of their disease, the recur-
rence, the progression and finally the survival. From the 22
patients with additional Cis findings thanks to fluorescence
cystoscopy, 14 had only low grade tumors or preneoplastic
lesions found with white light cystoscopy. This means that
without photodynamic diagnosis, these 14 patients would have
been clearly understaged, with probable unfavorable clinical
course. The other 8 patients of this group had already high
grade tumors found with conventional cystoscopy, however
without fluorescence cystoscopy they would be left with
untreated Cis lesions, which also means that they would be
at great risk of unfavorable prognosis. The above results high-
light the excellence of photodynamic diagnosis, a technique
that, according to the current literature, increases the diagnos-
tic rates for carcinoma in situ [13,14]. In our study 17 out of 70
patients had no findings with classical cystoscopy. Using
photodynamic cystoscopy we found that these patients had
flat lesions, otherwise invisible, and among them 7 patients
(41.2%) had Cis and 8 patients (47%) had dysplasia. There-
fore, if we were not equipped with this technology, 41.2% of
these patients would have been undiagnosed, suffering from
a cancer which demonstrates a very aggressive behavior
that leads very often to muscle invasive disease with dismal
prognosis. Of course, in this group of patients, false positive
rates are high to the level of 58.8%. However the large propor-
tion of these cases (47%) are dysplasias, which of course are
not cases of cancer but represent a premalignant lesion that
certainly requires a careful follow-up and which, in any case,
would be undiagnosed without photodynamic cystoscopy.c cystoscopy.
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revealed a significant number of dysplasias. More precisely
47% of patients with no findings in white light cystoscopy were
found to have dysplasia with blue light cystoscopy. Dysplasia
is a flat urothelial lesion with alterations that stand between
normal urothelium and Cis. This lesion can be primary or
secondary in patients with previous or concurrent urothelial
cancers. The incidence of primary dysplasia is not reliably
calculated because there are not enough well designed large
studies for this purpose [15]. The clinical significance of this
lesion is really important as it can potentially progress to
carcinoma in situ, papillary bladder cancer and even muscle-
invasive neoplasm in up to 19% for primary lesions and
30–36% for secondary lesions [16].
However, the histological distinction between dysplasia and
Cis is problematic. Formerly dysplasia was classified as mild,
moderate and severe and the distinction between these three
sub-categories was also difficult. Today it is recommended to
include severe dysplasia in Cis lesions and to avoid using the
term mild dysplasia. It is also difficult to distinguish dysplasia
from reactive atypia and for that it is suggested to use
immunohistochemical stains such as CK20, CD44, Ki-67 and
p53 [15].
In the present study very few cases of denuding cystitis were
detected (2 patients). This term was used to describe biopsies
with lack of urothelium and therefore it was difficult for
the pathologist to give a specific interpretation. This finding
can be attributed to small biopsy sample size, to the biopsy
technique or to biopsies of cystoscopically abnormal urothe-
lium that is denuded. In these cases it is suggested to perform
urinary cytology tests in order to seek for possible high grade
urothelial cancer [17].
A review of the literature, yielded similar results to the pre-
sent study. Ray et al. examined 23 patients with positive urine
cytology with white light and subsequently with blue light
cystoscopy. In 6 patients white light cystoscopy revealed
malignant or premalignant lesions. In 5 patients (22%) blue
light cystoscopy revealed additional pathology and more
specifically Cis in 3 patients and dysplasia in them. It is impres-
sive that in 3 out of 6 patients, photodynamic cystoscopy
revealed additional Cis, which means that without its use these
patients would be understaged [18].
Geavlete et al. performed white light cystoscopy in 181
patients and photodynamic cystoscopy (following white light
cystoscopy) in another 181 patients. The rate of diagnosis of
Ta tumors was 80.9% for the first group and 91.5% for the
second. This difference of 10.6% is statistically significant.
The diagnostic accuracy for T1 tumors was similar in the
two groups (88.5% and 93.4% respectively). The field where
blue light cystoscopy demonstrated its significant superiority
was the diagnosis of Cis where the diagnostic accuracy reached
94.3% compared to 62.9% of conventional cystoscopy.
Totally the diagnostic rate for every type of non-muscle
invasive tumors was 80.3% for the conventional procedure
compared to 92.2% for photodynamic diagnosis. This differ-
ence is statistically significant. The percentage of additional
findings with blue light cystoscopy was 35.2% for all kinds
of non-muscle invasive tumors. As for Cis, this technique
revealed 47.6% more cases that would otherwise have been
missed. This percentage is similar to the one of our study
and is correlated to reduced disease relapses. Indeed the
superiority of blue light cystoscopy is more than clearregarding recurrence rates at 1 and 2 years (21.6% and
31.2% respectively) compared to white light cystoscopy (31.2%
and 45.5% respectively) [19].
Jichlinski et al. published a study of 52 patients who
received preoperatively a bladder instillation of Hexvix and
then submitted white light cystoscopy followed by blue light
cystoscopy. Conventional cystoscopy diagnosed bladder
tumors in 33 patients while photodynamic cystoscopy revealed
lesions in 43 patients. Those extra 10 patients who had no
findings with classical cystoscopy had all Cis lesions that were
found thanks to photodynamic diagnosis technology. 11
patients who had findings with white light cystoscopy had
additional pathology that was revealed with blue light and 4
out of these patients had additional T1 disease that would
otherwise be missed. The sensitivity of conventional cysto-
scopy was 73% whereas that of photodynamic cystoscopy
was 96%, a difference that is of course significant. From 112
tumors totally diagnosed in these patients 47 were found solely
with blue light procedure. Only 4 tumors recognized with white
light cystoscopy were missed with blue light. Like in our study,
the number of additional tumors recognized with the aid of
photodynamic diagnosis is, at least, impressive. Moreover a
big percentage of these lesions was carcinoma in situ, which
means that these patients would be understaged without the
use of blue light technique and probably would have followed
a more unfavorable clinical course. In this study the rate of Cis
diagnosis reached the impressive 92% [20].
Schmidbauer et al. studied the effectiveness of photo-
dynamic cystoscopy as an additional procedure following
conventional white light cystoscopy. In this study 211 patients
had a preoperative instillation of HAL (hexaminolevulinate)
and then were submitted to white light cystoscopy followed
by photodynamic cystoscopy. 83 patients were diagnosed
with Cis. 77% of them were diagnosed with conventional
cystoscopy whereas 96% of them were diagnosed with photo-
dynamic cystoscopy. Blue light cystoscopy diagnosed addi-
tional 28% Cis cases in the whole group of patients, while in
the group of patients who had Cis as the only lesion, blue light
revealed additional 33% carcinomas in situ. In patients with
other bladder tumors the photodynamic procedure diagnosed
55% extra Cis compared to 4% extra Cis found by classical
cystoscopy, a difference that is of course statistically significant
(p< 0.0001). In total, blue light cystoscopy improved signifi-
cantly the diagnostic rates of Cis (97% vs 58% for white light
cystoscopy), Ta tumors (97% vs 88%) and dysplasia (94% vs
53%) [21].
Zaak et al. applied a similar protocol in 713 patients,
performing totally 1414 photodynamic cystoscopies. They
found 145 dysplasias from which 69.7% were recognized with
white light while 80.6% were diagnosed with blue light, a
difference that is statistically significant. As for carcinoma
in situ, 159 cases were diagnosed, 47.2% with white light and
91.2% with blue light cystoscopy, a difference which is even
bigger and more impressive [22].
There are numeral randomized controlled trials in the last
decade that have highlighted the superiority of photodynamic
cystoscopy over white light cystoscopy not only in diagnostic
sensitivity, as seen above, but also in recurrence rates. A
recently published study compared the early recurrence rates
between Good quality white light TUR-B (438 patients) and
Photodynamic assisted TUR-B (370 patients). Good quality
white light TUR-B strictly fulfilled the following criteria:
Reducing understaging of bladder cancer 93(1) cystoscopic mapping with bladder diagram, (2) documenta-
tion of complete neoplasm resection, (3) the procedure was
performed or supervised by an experienced urologist, (4)
detrusor muscle should always be present in the biopsy and
(5) mitomycin C bladder instillation in the first 24 h after
tumor resection. The recurrence rate at the first follow-up
cystoscopy was 30.9% for good quality white light cystoscopy
and 13.6% for photodynamic diagnosis (p< 0.001). The
superiority of blue light cystoscopy was more pronounced
for low and intermediate risk bladder cancers [23].
A recent review of the literature concluded that
Hexaminolevulinate-guided blue light cystoscopy leads to
better tumor identification than conventional white light
cystoscopy, thus permitting a more integrated tumor removal
which results in lower recurrence rates. From an economic
aspect, photodynamic diagnosis increases the initial operation
cost, compared to white light cystoscopy, however it reduces
over time the economic burden for managing bladder cancer
as it reduces recurrences and therefore limits additional
operations for the patients [24].
It is more than clear that photodynamic cystoscopy has
proven its value and tends to become the ‘‘gold standard”
for the management of flat urothelial lesions. However medical
technology keeps on inventing new competitive imaging
modalities. Narrow Band Imaging (NBI) is a technique that
improves bladder cancer detection through optical filtering
of the red spectrum of white light, which narrows the band-
width between blue light (415 nm) and green light (540 nm).
This narrow bandwidth is strongly absorbed by hemoglobin,
thus increasing the visibility of capillaries and blood vessels.
NBI improves the detection rate of bladder cancer compared
to white light cystoscopy (95% vs 75%). It also improves Cis
detection (95% detection rate compared to 68% detection rate
of conventional cystoscopy) [25]. It has higher sensitivity and
specificity than white light cystoscopy (94.3% and 84.7% vs
84.8% and 87%) [26]. NBI also reduces recurrence rates
compared to conventional cystoscopy (7.9% vs 17.8% for 1 year
follow-up and 22% vs 33% for 2 years follow-up) [25,27]. Com-
pared to photodynamic diagnosis, NBI does not require bladder
instillation. However studies comparing these techniques are
missing for the moment. The latest imaging modalities are Opti-
cal Coherence Tomography that permits real-time assessment
of bladder neoplasm invasiveness and Confocal Laser Endo-
microscopy which can differentiate high grade from low grade
bladder cancers [25,26]. These novel techniques, although
promising, should be considered experimental for the moment.
Conclusions
Conclusively photodynamic cystoscopy is the most efficient
diagnostic procedure for flat urothelial lesions and especially
for carcinoma in situ which is a high risk cancer with increased
rates of progression to muscle invasive disease, if left
untreated. It is significantly more sensitive than conventional
white light cystoscopy in Cis diagnosis, thus reducing under-
staging of the disease and consequently improving recurrence
and progression rates. In every case where Cis is suspected
(e.g. positive cytology) or in cases of recurrent disease blue
light cystoscopy should always be the first diagnostic option,
despite its increased cost, because it is the procedure with the
highest diagnostic rates for this urothelial lesion.Acknowledgments
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